Use of Goserelin for medical treatment of Uterine fibroids

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-3r88x9

Enrollment

Unknown

Registered

2018-07-24

Start date

2015-10-26

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibrois

Interventions

66 pacients were included. some laboratory tests were made: blood count, FSH, INR, KTTP, fibrinogeny and pelvic ultrasonography. These exams will be made each 3 months, 3 times, after the drug use. Go

Drug

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Woman; older than 18 year; diagnosis of uterine fibroids

Exclusion criteria

Exclusion criteria: Menopause; cancer; drug hypersensitivity

Design outcomes

Primary

Measure	Time frame
Reduction of uterus evaluated by ultrasonography 3 months after treatment, 50% of reduction is estimated;Good acceptance of the treatment evaluated by a treatment satisfaction questionnaire, applied in only one situation	—

Secondary

Measure	Time frame
Improvement of hemoglobin in laboratory exams ;Reduction of pain informed by the pacients, 3 months after treatment;Reduction of vaginal bleeding informed by the pacients, 3 months after treatment	—

Countries

Brazil

Contacts

Public ContactGleyse Rubio Oliveira

Universidade Federal do Paraná

gleyserubio@hotmail.com+51-041-996491434

Outcome results

None listed

Source: REBEC (via WHO ICTRP)